MedTrace Logo

Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

NCT00414206 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 343

Last updated 2010-11-23

Study results available
· View outcomes & findings →

Summary

This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration (NV-AMD).

Conditions

  • Macular Degeneration

Interventions

DRUG

Mecamylamine

DRUG

Placebo

Sponsors & Collaborators

  • CoMentis

    lead INDUSTRY

Principal Investigators

  • Carl Grove · CoMentis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-06-30
Completion
2009-09-30

Countries

  • Brazil
  • Czechia
  • Mexico
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00414206 on ClinicalTrials.gov